Detection of cytochrome P4503A (CYP3A) in human hepatic stellate cells

被引:14
|
作者
Parola, M
Robino, G
Bordone, R
Leonarduzzi, G
Casini, A
Pinzani, M
Neve, E
Bellomo, G
Dianzani, MU
IngelmanSundberg, M
Albano, E
机构
[1] UNIV TURIN,DEPT MED SCI,TURIN,ITALY
[2] UNIV FLORENCE,ALCOHOL RES CTR,I-50121 FLORENCE,ITALY
[3] UNIV FLORENCE,INST INTERNAL MED,I-50121 FLORENCE,ITALY
[4] KAROLINSKA INST,INST ENVIRONM MED,S-10401 STOCKHOLM,SWEDEN
关键词
D O I
10.1006/bbrc.1997.7307
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study we have investigated the occurrence of cytochrome P450 isoforms and of related cytochrome P450 reductase in human hepatic stellate cells (hHSC), a type of cell having relevant roles in physiopathological conditions of the liver. By performing; immunoblotting of hHSC microsomes and immunofluorescence analysis associated to confocal laser microscopy we detected only P450 enzymes belonging to the cytochrome P450 3A subfamily (CYP3A) as well as cytochrome P450 reductase. The presence of CYP3A was further indicated by detection of testosterone 6 beta-hydroxylase activity in hHSC microsomes. Other important human P450 forms were either undetectable (CYP1A2, CYP2E1, CYP2C8/9/19 and CYP4A) or bearly detectable (CYP1A1) in hHSC. This is the first study showing existence of active cytochrome P450 isoforms in human HSC. (C) 1997 Academic Press.
引用
收藏
页码:420 / 424
页数:5
相关论文
共 50 条
  • [21] Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease
    Dowling, TC
    Briglia, AE
    Fink, JC
    Hanes, DS
    Light, PD
    Stackiewicz, L
    Karyekar, CS
    Eddington, ND
    Weir, MR
    Henrich, WL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) : 427 - 434
  • [22] VARIABILITY IN ALFENTANIL PHARMACOKINETICS - THE ESSENTIAL ROLE OF CYTOCHROME P4503A
    KHARASCH, ED
    ANESTHESIOLOGY, 1994, 81 (3A) : A381 - A381
  • [23] PHARMACOLOGICAL PROBES OF CYTOCHROME P4503A ACTIVITY AND CYCLOSPORINE CONCENTRATIONS
    STEIN, CM
    KINIRONS, MT
    PINCUS, T
    WILKINSON, GR
    WOOD, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 192 - 192
  • [24] 伊曲康唑与细胞色素P4503A(CYP3A)底物和调节CYP3A活性的药物临床相互作用研究
    李茵
    张智洲
    北方药学, 2022, 19 (10) : 1 - 4
  • [25] Induction of cytochrome P4503A by the antiglucocorticoid mifepristone and a novel hypocholesterolaemic drug
    Williams, JA
    Chenery, RJ
    Berkhout, TA
    Hawksworth, GM
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (06) : 757 - 761
  • [26] Mechanism for the prevention of cholestasis involving cytochrome P4503A overexpression
    Paolini, M
    Pozzetti, L
    Piazza, F
    Guerra, MC
    Speroni, E
    Cantelli-Forti, G
    Roda, A
    JOURNAL OF INVESTIGATIVE MEDICINE, 2000, 48 (01) : 49 - 59
  • [27] Transport proteins and intestinal metabolism - P-glycoprotein and cytochrome P4503A
    Christians, U
    THERAPEUTIC DRUG MONITORING, 2004, 26 (02) : 104 - 106
  • [28] Evaluation of First-Pass Cytochrome P4503A (CYP3A) and P-glycoprotein Activities Using Felodipine and Hesperetin in Combination in Wistar Rats and Everted Rat Gut Sacs in Vitro
    Sridhar, V.
    Sandeep, M. Surya
    Babu, P. Ravindra
    Babu, K. Naveen
    PHYTOTHERAPY RESEARCH, 2014, 28 (05) : 699 - 705
  • [29] Nafcillin is a potent inducer of cytochrome P4503A activity in humans.
    Lang, CC
    Mustafa, AM
    Jamal, SK
    Mustafa, MR
    Mohamed, Z
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R458 - R458
  • [30] HUMAN LIVER CYTOCHROME P4503A BIOTRANSFORMATION OF THE CYCLOSPORINE DERIVATIVE SDZ IMM-125
    VICKERS, AEM
    MEYER, E
    DANNECKER, R
    KELLER, B
    TYNES, RE
    MAURER, G
    DRUG METABOLISM AND DISPOSITION, 1995, 23 (03) : 321 - 326